Business Context and Reporting Period
This Form 8-K filing by GlycoMimetics, Inc. (not Crescent Biopharma, Inc.) covers events occurring on March 9, 2017, and reported on March 13, 2017. The filing addresses changes to the Board of Directors, specifically the appointment of a new director and the resignation of a founding director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Appointment of Director: Scott Koenig, M.D., Ph.D., was appointed to the Board of Directors and the Nominating and Corporate Governance Committee. He serves as a Class II director with a term expiring at the 2019 Annual Meeting.
- Resignation of Director: John J. Baldwin, Ph.D., a founding board member, notified the Board of his intention to resign effective at the conclusion of the 2017 Annual Meeting of Stockholders (May 25, 2017).
Compensation and Governance Details
Upon appointment, Dr. Koenig received the following compensatory arrangements:
- Stock Options: A nonqualified stock option to purchase 22,000 shares at an exercise price of $6.59 (closing price on grant date). Vesting occurs in three equal installments over three years.
- Annual Retainers: $35,000 for board service and $4,000 for committee service.
- Future Grants: Eligible for an additional option to purchase 11,000 shares at each subsequent annual stockholder meeting, vesting over one year.
Dr. Koenig has no family relationship with other directors or officers, and no undisclosed arrangements exist regarding his selection.
Investor Verification Checklist
- Verify the exact date of Dr. Baldwin's resignation (conclusion of the May 25, 2017 Annual Meeting).
- Confirm the vesting schedule and exercise price ($6.59) of Dr. Koenig's initial 22,000 share option grant.
- Review Dr. Koenig's current roles at Macrogenics, Inc. and Applied Genetic Technologies Corporation for potential conflicts of interest.
- Check subsequent filings for the formal resignation of Dr. Baldwin post-Annual Meeting.